ARX 2002

Drug Profile

ARX 2002

Latest Information Update: 08 Feb 2005

Price : $50

At a glance

  • Originator AlphaRx
  • Class Anti-inflammatories
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

Most Recent Events

  • 08 Feb 2005 Discontinued - Preclinical for Neuroprotection in Canada (unspecified route)
  • 22 Oct 2002 Preclinical data from a media release have been added to the Neuroprotection/Inflammation pharmacodynamics section
  • 08 Nov 2001 Preclinical development for Neuroprotection/Inflammation (prevention) in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top